MedTrace Logo

Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

NCT00209651 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-11-01

No results posted yet for this study

Summary

To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative colorectal cancer.

Conditions

Interventions

DRUG

Campto, Topotesin

q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.

DRUG

TS-1

80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.

Sponsors & Collaborators

  • Hokkaido University Hospital

    collaborator OTHER

  • Hokkaido Gastrointestinal Cancer Study Group

    lead OTHER

Principal Investigators

  • Yoshito Komatsu, MD.PhD · Hokkaido Gastrointestinal Cancer Study Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2007-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209651 on ClinicalTrials.gov